Marlborough, MA-based medtech Hologic Inc. said the buy-out of SOMATEX Medical Technologies GmbH, which develops minimally invasive devices for tumor diagnostics, biopsy and interventional specialties, will allow Hologic to strengthen and further expand its breast cancer marker portfolio. It also enhances its sales presence in Europe by expanding its direct channel in Germany and its network of regional and international distributor partners.
“The acquisition of Somatex allows us to expand our biopsy portfolio by providing a suite of market-leading solutions that not only address our customers’ needs, but also improve the biopsy experience for their patients,” said Jennifer Meade, Hologic’s division president, breast and skeletal health solutions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?